(Q54535464)

31 May 2018

title

Dual inhibition of HER2 in breast cancer treatment. (English)

1 reference

31 May 2018

author

Michael Gnant

series ordinal

1

1 reference

31 May 2018

author name string

Guenther G Steger

series ordinal

2

1 reference

31 May 2018

language of work or name

English

0 references

publication date

17 January 2012

1 reference

31 May 2018

published in

The Lancet

1 reference

31 May 2018

volume

379

1 reference

31 May 2018

issue

9816

1 reference

31 May 2018

page(s)

596-598

1 reference

31 May 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3

7 January 2021

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3

7 January 2021

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3

7 January 2021

Pathologic Complete Response With Six Compared With Three Cycles of Neoadjuvant Epirubicin Plus Docetaxel and Granulocyte Colony-Stimulating Factor in Operable Breast Cancer: Results of ABCSG-14

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3

7 January 2021

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3

7 January 2021

Trastuzumab: A review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3

7 January 2021

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3

7 January 2021

Fighting overtreatment in adjuvant breast cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3

7 January 2021

Updated cost-effectiveness analysis of trastuzumab for early breast cancer: a UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960068-3

7 January 2021

10.1016/S0140-6736(12)60068-3

Identifiers

DOI

1 reference

31 May 2018

1 reference

31 May 2018